© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Dry mouth brings a quiet struggle to millions across North America, Europe, Asia, and beyond. From my own work with hospital supply chains, there’s always a new measure to balance price, quality, and reliability for products that make lives easier every day. Artificial saliva sits high on the list for clinics treating radiation therapy patients and the growing elderly populations in countries like the United States, Japan, and Germany. One would think a solution of water and electrolytes should be simple and cheap, yet the reality stretches across borders and economies, each country’s position shaped by raw material costs, manufacturing, regulations, and market size.
China stands out as a producer—not just because of its vast GMP-certified factory network but because it controls a major share of the world’s pharmaceutical raw materials. This low cost of inputs translates directly to lower artificial saliva prices, which many clinics in Brazil, India, Mexico, South Korea, and even the UK value while building their supply lists. Prices between 2022 and 2024 across Chinese manufacturers held steady, rarely fluctuating more than a few percent even when energy or shipping costs changed. I still remember the scramble clinics faced in 2021 across Canada and France, as European suppliers faced shortfalls and China’s robust logistics stepped in, filling shelves before patients ran dry. Labor costs in China remain lower than those in Australia, Italy, or Norway, and bulk shipping from Shanghai or Guangzhou to ports in Saudi Arabia, South Africa, and Russia keeps costs predictable. Local suppliers in places like Turkey or Poland rarely match China’s scale.
The US, Germany, Switzerland, and Japan push forward on innovation. Manufacturing plants in the US deploy more automation, achieving consistent quality. Some recent artificial saliva formulas feature improved lubricants and flavors, developed with research grants in the Netherlands or Sweden. Yet, this focus on tailored features and clinical studies in the UK and Canada often pushes costs up—the average bottle sold in those markets in 2023 priced over 60 percent more than in China. The European Union, with massive players like France and Spain, sets strict requirements for GMP certification and labelling, which in turn means audits, paperwork, and smaller batch runs. Meanwhile, growing emerging markets—Indonesia, Malaysia, Argentina, Nigeria, even Vietnam—look for a balance. They weigh the easy availability and low cost from China against any extra value in products coming from high-tech economies.
Artificial saliva hinges on common ingredients—water, sodium chloride, potassium, plus cellulose or xanthan gum for texture. China dominates global chemical supply, exporting low-cost base materials throughout Asia and beyond. India, boasting a pharmaceutical base nearly equal to China, still depends on some Chinese starters. The US and Germany source more raw materials domestically, though labor costs and utility bills are substantially higher. For countries like Saudi Arabia, Brazil, Italy, South Africa, and Mexico, the story plays out in import tariffs and logistics. Japan and Korea, with their advanced machinery, chase perfect process control for top-tier output, but don’t yet reach the supply volume found out of Chinese plants.
Supply chain shocks—like those in early 2020—forced even secure markets in the UK, Canada, and the US to scramble as suppliers struggled with input shortages and shipping bottlenecks. China, despite a temporary slowdown, brought production back online first, leveraging a vast exporter network to the UAE, Singapore, Israel, Saudi Arabia, and Chile. India ranks high due to its pharmaceutical capacity and export ambitions, but some African economies—Nigeria, Egypt—remain price-sensitive and often lack access to the latest formulations unless regional middlemen get involved. Smaller economies—like Thailand, Finland, Hungary, or Ireland—source either EU-approved products at hefty markups or Chinese bottles at a more affordable tally. Australia and New Zealand, often isolated by distance, pay a shipping premium for either US or Asian suppliers.
Prices held remarkably steady through 2022 and most of 2023. Chinese suppliers delivered consistent output with smaller economies like the Czech Republic, Israel, Greece, and Portugal consistently drawing from China’s bulk shipments. A spike touched the Japanese and Korean markets as local labor costs rose in late 2023, and manufacturers in the US passed on increased regulatory compliance fees to buyers in Mexico and Chile. Today, I see clinics in South Africa, Argentina, and Turkey more closely watching not only sticker prices but also the cost of keeping a buffer stock. For eastern European nations like Poland and Romania, Chinese wholesale prices undercut their traditional suppliers. Looking toward 2025, material cost forecasts suggest slight rises as global demand for pharmaceuticals stays strong. North American manufacturers expect rising wages and materials to push prices up a notch, but Chinese suppliers, with their efficient factories and economies of scale, remain poised to hold or even trim costs if shipping lanes stay open.
The top 20 GDP economies wield their own approaches. The United States leverages research-driven improvements, favoring quality and product consistency, with pricing strength built on brand and FDA approval. China wins on sheer affordable production and wide global supply. Japan and Germany pursue product quality, using automation and strict process controls. South Korea and Italy focus on niche blends and branding, targeting both home markets and select foreign buyers. Brazil and India play a role as both consumers and emergent manufacturers, selling to neighbors across Latin America, Africa, and Southeast Asia. The United Kingdom, France, Canada, and Spain import heavily, balancing cost and clinical preferences. Russia and Saudi Arabia watch currency swings and import routes. Indonesia, Mexico, Turkey, Australia, and the Netherlands respond to buffeting logistics and tariffs. Switzerland, with its high regulatory standards, aims for small, high-margin segments. Each country weighs its own priorities—price, innovation, supply security—and this dynamic mix drives competition and new solutions for hospitals worldwide.
From personal experience talking with hospital buyers in the UAE, Egypt, and Norway, every supply chain conversation boils down to reliability, cost, and speed. China’s GMP factories light the way for low-cost, high-volume availability, with reliable shipping for most of the world’s largest economies like Italy, Germany, the US, and India. US and European advances, especially in Germany and Japan, float possibilities for better patient experience, but high prices and regulatory headaches discourage many smaller economies from jumping in. Efficient international supply hinges on transparent pricing and steady access, not just for the wealthy countries, but for the growing middle economies like Poland, Thailand, Nigeria, and Chile. Investing in diversified manufacturing within regions—East Asia, the EU, South America—could spread risk and drive down prices. For the foreseeable future, the balance tilts to China: cost, scale, and supply chain muscle, shaping market choices for everyone from Canadian clinics to hospitals in Saudi Arabia.
